Peanut Oral Immunotherapy With or Without H and H Antihistamine Premedication for Peanut Allergy (PISCES): A Placebo-Controlled Randomized Clinical Trial.

Background: Current forms of peanut oral immunotherapy (OIT) are associated with side effects, and there is a lack of evidence addressing how to mitigate them.

Objective: To determine whether premedication with desloratadine and ranitidine results in fewer side effects during peanut OIT/desensitization.

Methods: A total of 43 patients with peanut allergy (mean age, 7.

Peanut allergy: Beyond the oral immunotherapy plateau.

Background: There are a lack of disease-modifying treatments for peanut allergy, which is lifelong in most instances. Oral immunotherapy has remained at the forefront of prospective treatments, though its efficacy is consistently undermined by the risk of adverse reactions and meager sustained effects.

Aim: This review discusses the current state of oral immunotherapy, its strengths and limitations, and the future of therapeutics for the treatment of peanut allergy.

Human BCR analysis of single-sorted, putative IgE memory B cells in food allergy.

R. Jimenez-Saiz, Y. Ellenbogen and K.

The Initiation of Th2 Immunity Towards Food Allergens.

In contrast with Th1 immune responses against pathogenic viruses and bacteria, the incipient events that generate Th2 responses remain less understood. One difficulty in the identification of universal operating principles stems from the diversity of entities against which cellular and molecular Th2 responses are produced. Such responses are launched against harmful macroscopic parasites and noxious substances, such as venoms, but also against largely innocuous allergens.